News

— INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection

— $3.8 million DOD contract extension to fund non-clinical safety studies; three-month seasonal prophylaxis Phase 2b study in at-risk populations, – elderly with comorbidities, including chronic lung diseases and diabetes.

— Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration.  

— ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations.

Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats

2022 ATS International Conference May 13-18, 2022, San Francisco, USA

ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT™

ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed
to boost innate immunity in patients at high risk of severe complications from respiratory infections

INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of complications that include individuals with COPD.

ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity

• First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal for most infections
• Company is recruiting study participants in the Sydney, Australia area

• Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051
• Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory therapy expert Ruth Tal-Singer, Ph.D., to Board of Directors

Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals

A novel nasal treatment developed to boost the natural human immune system to fight common colds and flu, has proved remarkably successful in reducing COVID-19 viral replication test results, released today, reveal.